1. Amisten S, Braun OO, Bengtsson A, Erlinge D. (2008) Gene expression profiling for the identification of G-protein coupled receptors in human platelets.
Thromb Res, 122 (1): 47-57.
[PMID:17920662]
2. Dancs PT, Ruisanchez É, Balogh A, Panta CR, Miklós Z, Nüsing RM, Aoki J, Chun J, Offermanns S, Tigyi G et al.. (2017) LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction.
FASEB J, 31 (4): 1547-1555.
[PMID:28069828]
3. de Souza CO, Paschoal VA, Sun X, Vishvanath L, Zhang Q, Shao M, Onodera T, Chen S, Joffin N, Bueno LM et al.. (2022) GPR92 activation in islet macrophages controls β cell function in a diet-induced obesity model.
J Clin Invest, 132 (21).
[PMID:36066975]
4. Hu J, Oda SK, Shotts K, Donovan EE, Strauch P, Pujanauski LM, Victorino F, Al-Shami A, Fujiwara Y, Tigyi G et al.. (2014) Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response.
J Immunol, 193 (1): 85-95.
[PMID:24890721]
5. Jongsma M, Matas-Rico E, Rzadkowski A, Jalink K, Moolenaar WH. (2011) LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor.
PLoS ONE, 6 (12): e29260.
[PMID:22195035]
6. Kotarsky K, Boketoft A, Bristulf J, Nilsson NE, Norberg A, Hansson S, Owman C, Sillard R, Leeb-Lundberg LM, Olde B. (2006) Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes.
J Pharmacol Exp Ther, 318 (2): 619-28.
[PMID:16651401]
7. Kozian DH, Evers A, Florian P, Wonerow P, Joho S, Nazare M. (2012) Selective non-lipid modulator of LPA5 activity in human platelets.
Bioorg Med Chem Lett, 22 (16): 5239-43.
[PMID:22801643]
8. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. (2006) GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5.
J Biol Chem, 281 (33): 23589-97.
[PMID:16774927]
9. Lin ME, Rivera RR, Chun J. (2012) Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain.
J Biol Chem, 287 (21): 17608-17.
[PMID:22461625]
10. Lin S, Yeruva S, He P, Singh AK, Zhang H, Chen M, Lamprecht G, de Jonge HR, Tse M, Donowitz M, Hogema BM, Chun J, Seidler U, Yun CC. (2010) Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fluid absorption via LPA(5) and NHERF2.
Gastroenterology, 138 (2): 649-58.
[PMID:19800338]
11. Lu Y, Wang Z, Li CM, Chen J, Dalton JT, Li W, Miller DD. (2010) Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents.
Bioorg Med Chem, 18 (2): 477-95.
[PMID:20056548]
12. Lundequist A, Boyce JA. (2011) LPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1β release.
PLoS ONE, 6 (3): e18192.
[PMID:21464938]
13. Mathew D, Kremer KN, Strauch P, Tigyi G, Pelanda R, Torres RM. (2019) LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling.
Front Immunol, 10: 1159.
[PMID:31231367]
14. Murai N, Hiyama H, Kiso T, Sekizawa T, Watabiki T, Oka H, Aoki T. (2017) Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents.
Neuropharmacology, 126: 97-107.
[PMID:28859883]
15. Oda SK, Strauch P, Fujiwara Y, Al-Shami A, Oravecz T, Tigyi G, Pelanda R, Torres RM. (2013) Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.
Cancer Immunol Res, 1 (4): 245-55.
[PMID:24455753]
16. Oh DY, Yoon JM, Moon MJ, Hwang JI, Choe H, Lee JY, Kim JI, Kim S, Rhim H, O'Dell DK, Walker JM, Na HS, Lee MG, Kwon HB, Kim K, Seong JY. (2008) Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92.
J Biol Chem, 283 (30): 21054-64.
[PMID:18499677]
17. Ohuchi H, Hamada A, Matsuda H, Takagi A, Tanaka M, Aoki J, Arai H, Noji S. (2008) Expression patterns of the lysophospholipid receptor genes during mouse early development.
Dev Dyn, 237 (11): 3280-94.
[PMID:18924241]
18. Plastira I, Bernhart E, Goeritzer M, Reicher H, Kumble VB, Kogelnik N, Wintersperger A, Hammer A, Schlager S, Jandl K et al.. (2016) 1-Oleyl-lysophosphatidic acid (LPA) promotes polarization of BV-2 and primary murine microglia towards an M1-like phenotype.
J Neuroinflammation, 13 (1): 205.
[PMID:27565558]
19. Southern C, Cook JM, Neetoo-Isseljee Z, Taylor DL, Kettleborough CA, Merritt A, Bassoni DL, Raab WJ, Quinn E, Wehrman TS et al.. (2013) Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein-Coupled Receptors.
J Biomol Screen, 18 (5): 599-609.
[PMID:23396314]
20. Williams JR, Khandoga AL, Goyal P, Fells JI, Perygin DH, Siess W, Parrill AL, Tigyi G, Fujiwara Y. (2009) Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.
J Biol Chem, 284 (25): 17304-19.
[PMID:19366702]
21. Yung YC, Stoddard NC, Chun J. (2014) LPA receptor signaling: pharmacology, physiology, and pathophysiology.
J Lipid Res, 55 (7): 1192-1214.
[PMID:24643338]
22. Zhang D, Decker AM, Woodhouse K, Snyder R, Patel P, Harris DL, Tao YX, Li JX, Zhang Y. (2022) Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects.
Eur J Med Chem, 243: 114741.
[PMID:36126387]